McGraw-Hill Book Company Australia
[PubMed] [Google Scholar] 90.Vaux E.C., Taylor D.J., Altmann P., Rajagopalan B., Graham K., Cooper R., Bonomo Y., Styles P
Phase 3 trials under the TRIUMPH program are ongoing, testing retatrutide in obesity, type 2 diabetes, sleep apnea, knee osteoarthritis, and chronic kidney disease
Because NNMT consumes both nicotinamide and SAM, inhibiting the enzyme may alter intracellular 1-MNA, NAD + , SAM, and SAH levels under some experimental conditions
"They lose weight, which is a positive thing," says Warren Yacawych of the University of Michigan, "but they experience such severe nausea and vomiting that patients stop treatment." So at this year's Society for Neuroscience meeting in San Diego, Yacawych and other researchers held a session to describe their efforts to understand and solve the side-effect problem